^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MYTX-011

    i
    Other names: MYTX-011
    Company:
    Mythic Therap
    Drug class:
    Microtubule inhibitor, c-MET-targeted antibody-drug conjugate
    Related drugs:
    2ms
    KisMET-01: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=250, Recruiting, Mythic Therapeutics | N=150 --> 250
    Enrollment change
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation • MET mutation
    |
    MYTX-011
    7ms
    MYTX-011: A pH-Dependent Anti-c-MET Antibody-Drug Conjugate Designed for Enhanced Payload Delivery to c-MET-Expressing Tumor Cells. (PubMed, Mol Cancer Ther)
    These results highlight the potential of MYTX-011 for treating a broader range of patients with NSCLC with c-MET expression than other c-MET-targeting ADCs. A first-in-human study is ongoing to determine the safety, tolerability, and preliminary efficacy of MYTX-011 in patients with NSCLC (NCT05652868).
    Journal • Tumor cell
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MYTX-011
    12ms
    KisMET-01: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=150, Recruiting, Mythic Therapeutics
    Trial completion date • Trial primary completion date
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation • MET mutation
    |
    MYTX-011
    almost2years
    MYTX-011: A novel cMET-targeting antibody drug conjugate (ADC) engineered to increase on-target uptake in and efficacy against cMET expressing tumors (AACR 2023)
    PK and toxicity studies in cynomolgus monkeys revealed that MYTX-011 exhibited favorable PK characteristics, and a toxicity profile similar to previously described MMAE-based ADCs. Together, these findings highlight the potential of MYTX-011 as a therapeutic candidate for treating a broader range of cMET+ malignancies than other cMET-ADCs.
    Clinical
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET expression
    |
    MYTX-011
    almost2years
    KisMET-01: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=150, Recruiting, Mythic Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation • MET mutation
    |
    MYTX-011
    2years
    Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=150, Not yet recruiting, Mythic Therapeutics
    New P1 trial
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation • MET mutation
    |
    MYTX-011